Open AccessProstate cancer screening: and yet it moves!
Author(s) -
Maciej Kwiatkowski,
Marco Randazzo,
Luis Kluth,
Lukas Manka,
Andreas Huber,
Franz Recker
Publication year - 2015
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/1008-682x.143310
Subject(s) - prostate cancer , prostate cancer screening , medicine , harm , prostate specific antigen , overdiagnosis , gynecology , randomized controlled trial , oncology , family medicine , cancer , psychology , social psychology
The debate of prostate cancer (PCa) screening has been shaped over decades. There is a plethora of articles in the literature supporting as well as declining prostate-specific antigen (PSA) screening. Does screening decrease PCa mortality? With the long-term results of the European Randomized Study of Screening for Prostate (ERSPC) the answer is clearly YES. It moves! However, in medicine there are no benefits without any harm and thus, screening has to be performed in targeted and smart way-or in other words-in a risk-adapted fashion when compared with the way it was done in the past. Here, we discuss the main findings of the ERSPC trials and provide insights on how the future screening strategies should be implemented.